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Treatment With Mycophenolate and Cyclophosphamide 
Leads to Clinically Meaningful Improvements in Patient-
Reported Outcomes in Scleroderma Lung Disease: Results 
of Scleroderma Lung Study II
Elizabeth R. Volkmann,1  Donald P. Tashkin,1 Holly LeClair,1 Michael D. Roth,1 Grace Kim,1  
Jonathan Goldin,1 Philip J. Clements,1 Daniel E. Furst,2 and Dinesh Khanna3
Objective. Our objective was to determine if treatment with cyclophosphamide (CYC) and mycophenolate mofetil 
(MMF) improves patient-reported outcomes (PROs) among patients with systemic sclerosis-related interstitial lung 
disease (SSc-ILD).
Methods. This study examined PROs in patients with SSc-ILD (N = 142) who participated in the Scleroderma Lung 
Study II, a randomized controlled trial comparing MMF for 2 years with oral CYC for 1 year followed by 1 year of a 
placebo. Joint models were created to evaluate the course of PROs over 2 years. The difference in PRO scores from 
baseline to 24 months was measured, and the percentage of patients meeting the minimum clinically important difference 
(MCID) was calculated. Correlations between PROs and SSc-ILD disease severity measures were also examined.
Results. Treatment with CYC and MMF led to improvements in several PROs with no between-treatment 
differences. Scores for the Transitional Dyspnea Index (TDI) and St. George’s Respiratory Questionnaire (SGRQ) 
improved significantly over 2 years, and 29%/24% and 28%/25% of participants in the CYC/MMF groups met or 
exceeded the MCID estimates for TDI and SGRQ, respectively. At baseline, the forced vital capacity (FVC) percentage 
predicted (FVC%-predicted) did not correlate with the Baseline Dyspnea Index or SGRQ. However, improvements in 
the FVC%-predicted were weakly associated with improvements in dyspnea (assessed by the TDI) and SGRQ scores.
Conclusion. Treatment with CYC and MMF improved overall health-related quality of life in patients with SSc-ILD. 
The relationship between PRO measures and the FVC was relatively weak, suggesting that PROs provide complementary 
information about treatment efficacy not captured by changes in the FVC alone in this patient population.
INTRODUCTION
Patient-reported outcomes (PROs) directly assess how 
patients feel and function from their own perspective. For com-
plex systemic diseases, such as systemic sclerosis, PROs play 
a central role in providing insight into a patient’s experience living 
with this disease (1–3). Specifically, PROs measure symptoms, 
such as dyspnea, and health-related quality of life (HRQOL), and 
they may reveal treatment effects, such as pulmonary function, 
that are not captured by other measures.
In systemic sclerosis (SSc) and interstitial lung disease 
(ILD) (SSc-ILD) therapeutic research trials, PROs have included 
dyspnea indexes (4–6), cough questionnaires (7,8), and HRQOL 
surveys (4). Although other outcomes, such as the forced vital 
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capacity (FVC) percentage predicted (FVC%-predicted), shed 
light on treatment-related changes in pulmonary physiology, only 
the PROs provide information about how a particular treatment 
affects a patient’s experience with the disease. In some SSc-ILD 
trials, improvements in PRO scores have paralleled improvements 
observed in the FVC%-predicted (4), whereas in other trials, 
changes in PRO scores do not parallel changes in the FVC%- 
predicted (5). These conflicting results suggest that PROs may 
be measuring distinct treatment-related effects that are important 
to consider in caring for patients with SSc-ILD.
The present study sought to evaluate changes in PROs in 
the Scleroderma Lung Study (SLS) II, a randomized controlled 
trial comparing the safety and efficacy of mycophenolate mofetil 
(MMF) and oral cyclophosphamide (CYC) for treating SSc-ILD 
(9). The results of SLS II demonstrated that the FVC%-predicted 
improved significantly over 24 months in both treatment arms 
(average FVC%-predicted improvement: MMF 3.3%; CYC 3.0%) 
(9). The primary objective of this study was to investigate how 
specific PROs changed in response to therapy with CYC and 
MMF. A secondary goal was to determine whether changes in 
PROs correlate with changes in the FVC%-predicted in SLS II.
PATIENTS AND METHODS
Patient population. Participants of SLS II were all adults 
(18-75 years old) with SSc-ILD and either limited SSc (lcSSc) or 
diffuse SSc (dcSSc) (10) with active ILD, defined as the presence 
of both a restrictive to borderline restrictive ventilatory impairment 
(FVC%-predicted: less than 80%-85% but greater than or equal 
to 45%) and the presence of any ground glass opacity (GGO) 
(hazy opacity through which normal lung markings can be dis-
cerned) on high-resolution computed tomography (HRCT). Partic-
ipants also had to have exertional dyspnea based on the Mahler 
Baseline Dyspnea Index (BDI) (11) and a disease duration of less 
than or equal to 7 years from the onset of the first non-Raynaud’s 
symptom of SSc. Key exclusion criteria included pulmonary 
hypertension, clinically significant abnormalities on HRCT not 
attributable to SSc, smoking within the past 6 months, and 
evidence of significant airflow obstruction, defined as a ratio of 
the forced expired volume in 1 second to the FVC%-predicted 
of 65% or less. The study was approved by the Office of Human 
Research Protection Program at University of California, Los 
Angeles (UCLA) (Institutional Review Board [IRB] No. 11-002659- 
CR-00005) and by the IRBs of all 14 participating centers.
SLS II Study Design. Participants in SLS II were randomized 
to receive either oral CYC for 1 year followed by 1 year of a pla-
cebo or MMF for 2 years (9). The primary end point for the study 
was the course of the FVC%-predicted, measured every 3 months 
over 2 years.  Thoracic HRCT imaging was obtained at baseline 
and 2 years, and a computer-aided design scoring system was 
employed to provide quantitative measures of different patterns of 
ILD as previously described (12). The quantitative ILD (QILD) score 
was the sum of all abnormally classified scores, including scores 
for quantitative lung fibrosis (QLF) (linear reticular markings with 
architectural distortion), GGO, and honeycomb changes (clustered 
air-filled cysts with dense walls). Scores were calculated as a per-
centage of total counted voxels for both the whole lung (WL), which 
included both lungs, and the zone of maximal involvement (ZM). The 
complete details of the SLS II protocol appear in the supplementary 
web appendix accompanying the main SLS II publication (9).
PROs. The following PROs were examined in SLS II: Short 
Form 36 (SF-36) (13), the Health Assessment Questionnaire Dis-
ability Index (HAQ-DI) (14), the BDI (11), the Transitional Dyspnea 
Index (TDI) (15), the Leicester Cough Questionnaire (LCQ) (16), 
St. George’s Respiratory Questionnaire (SGRQ) (17), and the 
UCLA Scleroderma Clinical Trials Consortium (SCTC) Gastroin-
testinal Tract 2.0 (GIT 2.0) (18). Each PRO aimed to address a 
unique aspect of the disease experience of SSc-ILD. For instance, 
the SF-36 measures HRQOL and consists of eight scales with 
both physical and mental components of HRQOL (13). For this 
analysis, we focused on the scores for the physical component 
summary (PCS) and mental component summary (MCS). The 
HAQ-DI measures functional ability in patients with musculoskel-
etal conditions (14) and has been studied extensively in patients 
with SSc (19,20).
The PROs targeting respiratory symptoms included the BDI, 
the TDI, the LCQ, and SGRQ. The BDI assesses patients’ per-
ception of their breathlessness at baseline based on three cate-
gories (functional impairment, magnitude of task, and magnitude 
of effort), whereas the TDI measures the change in dyspnea 
from baseline in each of these categories, the results of which 
are summed into a total score (11,15). The LCQ is a 19-item 
HRQOL measure of chronic cough and is highly responsive to 
change (16). It is a patient-derived questionnaire; therefore, it con-
tains items, domains, and response scales that are clinically mean-
ingful to the patient. SGRQ is a 50-item questionnaire that was 
originally designed to measure the impact of overall health, daily 
life, and perceived well-being in patients with obstructive airway 
disease (21). However, prior studies have demonstrated that it 
correlates well with other measures of disease activity in patients 
with SSc-ILD (17) and is responsive to change in patients with 
dcSSc (22).
The UCLA SCTC GIT 2.0 is an instrument that measures gas-
trointestinal tract involvement in SSc and contains 34 items from 
seven scales (reflux, distention/bloating, diarrhea, fecal soilage, 
constipation, emotional well-being, and social functioning) (18). 
It has been translated into several languages and has also been 
found to discriminate between patients with and without objective 
evidence of gastrointestinal tract involvement (23). A recent study 
from six international SSc centers demonstrated that the reflux 
scale is sensitive to change in patients with SSc and active gas-
troesophageal reflux disease (24).
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The SF-36, HAQ-DI, LCQ and SGRQ scores were assessed 
at baseline and every 3 months during the study, whereas the TDI 
score was assessed at baseline and every 6 months during the 
study. The GIT 2.0 score was assessed at baseline and at 12 and 
24 months.
Statistical analysis. Summary statistics were generated 
for the SF-36, HAQ-DI, BDI, LCQ, SGRQ, and GIT 2.0 scores 
at baseline. Between-group comparisons in baseline PRO scores 
were performed using the Student’s t test.
The percentage of participants who met or exceeded the 
threshold for the minimum clinically important difference (MCID) 
for each of the PROs was analyzed using the χ2 test. The MCID 
is the smallest improvement in the PRO score necessary for the 
patients to perceive an improvement that is meaningful to them 
(25). MCID estimates are captured at a group level. The MCID for 
each PRO is summarized in Table 1 (26–31).
We used Pearson’s correlation coefficient to examine the rela-
tionship between baseline PRO scores and the extent of physio-
logic impairment (baseline FVC%-predicted and diffusing capacity 
for carbon monoxide [DLCO]), structural lung disease (QLF and 
QILD), and the modified Rodnan skin score (mRSS) as well as the 
relationship between the change in PRO scores and the change 
in FVC%-predicted, DLCO percentage predicted (DLCO%- 
predicted), mRSS, QLF, and QILD scores. We included all of the 
radiographic imaging scores because we wanted to understand 
whether changes in certain structural parameters correlated bet-
ter with PROs (eg, improvement in the total lung versus improve-
ment in the ZM). Pearson correlation coefficients were interpreted 
as proposed by Cohen (32): 0.1, small correlation; 0.3, medium 
correlation; and 0.5, large correlation. We did not correct for mul-
tiple hypothesis testing.
For the SGRQ, TDI, and HAQ-DI scores, an inferential 
joint model was used to examine the course of the PRO score 
over the course of the study. The joint model consisted of a mixed- 
effects model for longitudinal outcomes and a  survival model 
to handle nonignorable missing data caused by study dropout, 
treatment failure, or death (ie, likely related to disease or treat-
ment and therefore not random) (33). Fixed effects for the longi-
tudinal portion of the joint model included treatment assignment, 
a time trend, the PRO at baseline, and a treatment group by time 
trend interaction. The time trend was modeled by linear splines 
with knots at 12 and 21 months, except for the TDI, which only 
included a knot at 12 months because the TDI was only collected 
every 6 months.
Statistical analyses were performed using SAS version 9.4 
(SAS Institute, Inc.), except for the joint modeling, which was con-
ducted in R (R Foundation for Statistical Computing). P values less 
than 0.05 were considered statistically significant.
RESULTS
Main SLS II study findings. In SLS II, 73 patients with 
SSc-ILD were randomized to receive CYC, and 69 patients were 
randomized to receive MMF. Participants were predominantly 
women (74%) with an average age of 52 years, an average dis-
ease duration of 2.6 years, and a moderate degree of restriction 
on pulmonary function testing (9). Both treatment arms had similar 
scores for PROs at baseline (see Supplementary Table S1 for a 
complete list of baseline characteristics). Moreover, both treat-
ment arms experienced a significant improvement in the course 
of the FVC%-predicted over 24 months, with an average absolute 
improvement of 3.0 and 3.3 in the CYC and MMF arms, respec-
tively (9). In addition to improvement in the FVC%-predicted from 
baseline, treatment with MMF and CYC also led to significant 
improvements in the course of the mRSS as well as the QILD-WL 
score, with no between-treatment differences (9,34).
Treatment with CYC and MMF improves breath-
lessness and respiratory HRQOL. Supporting the results of 
the primary SLS II article, the present analysis found significant 
improvements in overall HRQOL in patients who participated in 
SLS II. Participants randomized to receive CYC and MMF expe-
rienced significant improvements in self-reported dyspnea and 
respiratory-related HRQOL based on the TDI and SGRQ, respec-
tively. Figure 1 demonstrates the course of the TDI score in SLS II 
based on the joint model analysis. At 12, 18, and 24 months, par-
ticipants in both the CYC and MMF arms experienced significant 
improvements in breathlessness relative to baseline, as measured 
by the TDI (Figure 1, Supplementary Table S2). There was no dif-
ference in the course of the TDI score between participants rand-
omized to receive CYC versus those randomized to receive MMF 
(Supplementary Table S2).
Table 1. MCID scores for the PRO instruments examined in SLS II
Instrument Description MCID Interpretation
SF-36 (26) Measures health status ≥5 Increase in score indicates improvement
HAQ-DI (27) Measures functional ability ≤−0.14 Decrease in score indicates improvement
TDI (29) Measures dyspnea ≥1 Increase in score indicates improvement
LCQ (30) Measures cough ≥1.5 Increase in score indicates improvement
SGRQ (31) Measures health status and well-being ≤−4.0 Decrease in score indicates improvement
UCLA GIT 2.0. (total score) (28) Measures gastrointestinal tract involvement <−0.21 Decrease in score indicates improvement
Abbreviation: HAQ-DI, Health Assessment Questionnaire Disability Index; LCQ, Leicester Cough Questionnaire; MCID, minimum clinically 
important difference; PRO, patient-reported outcome; SF-36, Short Form 36; SGRQ, St. George’s Respiratory Questionnaire; SLS, Scleroderma 
Lung Study; TDI, Transitional Dyspnea Index; UCLA GIT 2.0, University of California, Los Angeles Gastrointestinal Tract 2.0.
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Similar to the TDI, the course of the SGRQ score improved 
over the course of SLS II based on the joint model analysis (Figure 
2, Supplementary Table S3). At 15, 18, and 24 months, partic-
ipants randomized to receive CYC experienced statistically sig-
nificant improvements in the SGRQ score relative to baseline, 
whereas at 18 and 24 months, participants randomized to receive 
MMF experienced significant improvements in the SGRQ score 
relative to baseline. There was a slight increase in SGRQ scores 
(worsening) from 21 to 24 months, when participants who had 
prematurely stopped the study drug were invited to return for 
the final study visit. There was no difference in the course of the 
SGRQ score between participants randomized to receive CYC 
and those randomized to receive MMF (Supplementary Table S3).
The course of the HAQ-DI score also improved over the 
course of the study, although the change was not statistically sig-
nificant within or between treatment arms (Supplementary Figure 
S1, Supplementary Table S4). For a summary of the change in 
scores for each PRO, please see Supplementary Table S5.
Proportion of participants treated with MMF and CYC 
whose PRO scores improved more than the MCID. For each 
PRO, a number of participants in the CYC and MMF arms met or 
exceeded the MCID estimates at both 12 and 24 months (Table 2). 
There were no differences between treatment arms in the pro-
portion of participants whose PRO scores improved more than 
the MCID at either time point. For SGRQ, 28% and 24% of partic-
ipants randomized to receive CYC and MMF, respectively, met or 
exceeded the MCID for this outcome at 24 months. For the TDI, 
29% and 24% of participants randomized to receive CYC and 
MMF, respectively, met or exceeded the MCID for this outcome at 
24 months. For the HAQ-DI, 17% and 14% of participants rand-
omized to receive CYC and MMF, respectively, met or exceeded 
the MCID for this outcome at 24 months.
Overall generic health status also improved for a number of 
participants based on the results of the SF-36 (Table 2). In partici-
pants randomized to receive both CYC and MMF, 17% of partici-
pants met or exceeded the MCID for the SF-36 PCS at 24 months. 
For the SF-36 MCS, 20% and 21% of participants randomized to 
receive CYC and MMF, respectively, met or exceeded the MCID 
for this outcome at 24 months. A relatively smaller percentage of 
participants met or exceeded the MCID for the total GIT 2.0 score 
at 24 months (CYC: 13%; MMF: 10%) (Table 2).
Relationship between PRO measures and objec-
tive SSc-ILD disease severity measures. At baseline, the 
FVC%-predicted did not correlate with any of the PRO measures, 
except for a weak correlation with the LCQ score (Table 3). There 
were medium correlations between the DLCO%-predicted and 
the LCQ and SGRQ scores (Table 3). The BDI, SGRQ, and LCQ 
scores all correlated with the extent of quantitative radiographic 
fibrosis and ILD, demonstrating that patients with more self- 
reported dyspnea at baseline had worse diffusing capacity and 
increased extent of radiographic fibrosis. The HAQ-DI score did 
not correlate with any of the objective measures of SSc-ILD dis-
ease severity, nor did the SF-36 MCS score, GIT 2.0 total score, 
or GIT 2.0 reflux score (Table 3).
The change in the FVC%-predicted significantly correlated 
with the change in the SF-36, HAQ-DI, TDI, and SGRQ scores at 
24 months, indicating that patients who experienced an improve-
ment in their FVC%-predicted experienced parallel improve-
ments in their dyspnea and HRQOL (Table 4). Of all of the PRO 
Figure 1. Course of the St. George’s Respiratory Questionnaire 
(SGRQ) score over 24 months by treatment arm. The solid line 
represents cyclophosphamide (CYC), and the dotted line represents 
mycophenolate mofetil (MMF). The horizontal line represents the 
mean baseline SGRQ score for the entire Scleroderma Lung Study 
II cohort. aA significant change from baseline within the MMF arm at 
15, 18, and 21 months. bA significant change from baseline within 
the CYC arm at 18, 21, and 24 months. Please see Supplemental 
Table S3 for a complete summary of joint model results.
Figure 2. Course of the Transitional Dyspnea Index (TDI) score 
over 24 months by treatment arm. The solid line represents 
cyclophosphamide (CYC), and the dotted line represents 
mycophenolate mofetil (MMF). The horizontal line represents the 
mean Baseline Dyspnea Index score for the entire Scleroderma 
Lung Study II cohort. aA significant change from baseline within the 
MMF arm at 12, 18, and 24 months. bA significant change from 
baseline within the CYC arm at 12, 18, and 24 months. Please 
see Supplemental Table S2 for a complete summary of joint model 
results.
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measures, the change in breathlessness (assessed by the TDI) 
correlated significantly with changes in the most objective meas-
ures of SSc-ILD severity (FVC%-predicted, DLCO%-predicted, 
QLF-WL, QILD-LM, and QILD-WL), whereas the change in the 
SGRQ score correlated only with the change in the FVC%- 
predicted, DLCO%-predicted, and QILD-LM score but not with 
changes in the other radiographic ILD and fibrosis scores. Sim-
ilarly, the change in the HAQ-DI score only modestly correlated 
with the change in the FVC%-predicted and DLCO%-predicted 
(Table 4).
The relationship between cutaneous sclerosis and 
PROs in patients with SSc-ILD. The baseline mRSS corre-
lated significantly with the baseline HAQ-DI and LCQ scores in all 
patients and in patients with dcSSc but not in patients with lcSSc 
(Table 3). At 24 months, 42% and 49% of patients randomized to 
the CYC and MMF arms, respectively, met or exceeded the MCID 
for the mRSS (defined as a decline of five points). An improvement 
in the mRSS from baseline to 24 months correlated significantly 
with an improvement in the SF-36, HAQ-DI, and TDI scores in all 
patients (Table 4). Improvements in the mRSS correlated signif-
icantly with improvements in the SF-36 PCS, HAQ-DI, and TDI 
scores in patients with dcSSc, but only an improvement in the 
HAQ-DI score was associated with an improvement in the mRSS 
in patients with lcSSc (Table 4).
Of note, there were no significant correlations between the 
baseline mRSS and FVC%-predicted in all patients or in patients 
with dcSSc or lcSSc. There was a significant correlation between 
improvement in the mRSS and an improvement in the FVC%- 
predicted in all patients (r = −0.24) and in patients with dcSSc 
(r = −0.28) but not in patients with lcSSc.
DISCUSSION
Treatment with immunosuppression is typically the first-line 
therapeutic approach for patients with SSc-ILD (35). The results 
of this study affirm that this approach improves PRO measures, 
in addition to lung function and radiographic measures of ILD, in 
Table 2. Number of participants meeting the MCID scores for the PRO instruments examined in SLS II at 12 
and 24 mo
PRO
n (%) at 12 Mo
Pa
n (%) at 24 mo
PaCYC MMF CYC MMF
SF-36 PCS 19 (16.9) 17 (15.0) 0.55 18 (17.0) 18 (17.0) 1
SF-36 MCS 23 (20.4) 22 (19.5) 0.67 21 (19.8) 22 (20.8) 0.84
HAQ-DI 20 (17.7) 15 (13.3) 0.23 18 (17.0) 15 (14.2) 0.53
TDI 21 (21.9) 19 (19.8) 0.56 23 (29.1) 19 (24.1) 0.31
LCQ 17 (15.6) 11 (10.1) 0.17 16 (15.4) 13 (12.5) 0.51
SGRQ 31 (27.7) 28 (25.0) 0.44 29 (27.6) 25 (23.8) 0.5
UCLA GIT 2.0 (total score) 16 (14.3) 11 (9.8) 0.23 14 (13.3) 10 (9.52) 0.38
Abbreviation: CYC, cyclophosphamide; HAQ-DI, Health Assessment Questionnaire Disability Index; LCQ, Leicester 
Cough Questionnaire; MCID, minimum clinically important difference; MCS, mental component summary; MMF, 
mycophenolate mofetil; PCS, physical component summary; PRO, patient-reported outcome; SF-36, Short Form 
36; SGRQ, St. George’s Respiratory Questionnaire; SLS, Scleroderma Lung Study; TDI, Transitional Dyspnea 
Index; UCLA GIT 2.0, University of California, Los Angeles Gastrointestinal Tract 2.0.
aP value for differences between treatment arms. 
Table 3. Baseline correlations between PROs and objective measures of SSc-ILD disease severity in SLS IIa
  FVC% DLCO% QLF-ZM QLF-WL QILD-ZM QILD-WL mRSS, All mRSS, dcSSc mRSS, lcSSc
SF-36 PCS 0.05 0.18* −0.02 −0.07 −0.13 −0.16 −0.14 −0.03 0.18
SF-36 MCS 0.1 0.06 −0.08 −0.12 −0.13 −0.12 −0.01 0.00 −0.09
HAQ-DI 0.07 0.01 −0.10 −0.07 0.01 0.04 0.41* 0.30* −0.01
BDI 0.09 0.22* −0.18* −0.19* −0.25* −0.25* 0.11 0.18 0.07
LCQ 0.20* 0.33* −0.27* −0.32* −0.32* −0.33* 0.26* 0.29* 0.08
SGRQ −0.14 −0.30* 0.21* 0.29* 0.30* 0.33* −0.11 −0.15 −0.07
UCLA GIT 2.0 
(total score)
−0.08 −0.06 −0.09 0.03 −0.02 0.06 −0.04 −0.11 −0.05
UCLA GIT 2.0 
(reflux)
−0.06 −0.09 −0.10 0.02 0.00 0.07 −0.04 −0.24* 0.08
Abbreviation: BDI, Baseline Dyspnea Index; dcSSc, diffuse systemic sclerosis; DLCO%, diffusing capacity for carbon monoxide; FVC%, forced 
vital capacity; HAQ-DI, Health Assessment Questionnaire Disability Index; LCQ, Leicester Cough Questionnaire; lcSSc, limited systemic sclerosis; 
MCS, mental component summary; mRSS, modified Rodnan skin score; PCS, physical component summary; QILD, quantitative interstitial lung 
disease; QLF, quantitative lung fibrosis; SF-36, Short Form 36; SGRQ, St. George’s Respiratory Questionnaire; SLS, Scleroderma Lung Study; SSc-
ILD, systemic sclerosis-related interstitial lung disease; UCLA GIT 2.0, University of California, Los Angeles Gastrointestinal Tract 2.0; WL, whole 
lung; ZM, zone of maximal involvement.
a Bold values denote medium correlation coefficients (r ≥ 0.3). 
*P < 0.05. 
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patients with this condition. Specifically, this study found that treat-
ment with MMF and CYC led to significant and clinically mean-
ingful improvements in self-reported dyspnea, health status, and 
physical function in patients with SSc-ILD.
Although the FVC is frequently used as the primary out-
come measure in SSc-ILD clinical trials, changes in the FVC may 
not consistently translate into clinically meaningful improvements 
from a patient’s perspective. For example, in the SENSCIS trial, 
patients with SSc-ILD treated with nintedanib had a lower rate 
of annual FVC decline than those receiving a placebo (treatment 
difference of 41 ml); however, there was no significant difference 
in PROs (based on SGRQ or the HAQ-DI) between treatment 
groups (5). In contrast, both SLS I (6) and our current analyses 
showed clinically meaningful improvements in PROs with treat-
ment of SSc-ILD. Both SLS II (9) and SENSCIS (5) had similar 
baseline characteristics (FVC%-predicted, DLCO%-predicted, 
disease duration, mRSS, and SGRQ); however, there are several 
plausible explanations for these discrepancies. First, in SLS II (9), 
there was an overall trend for improvement in the FVC%- 
predicted, whereas in SENSCIS (5), there was an overall trend for a 
decline in the FVC%-predicted. Second, PROs capture the overall 
impact of an intervention on the whole person. Treatment with 
MMF and CYC favorably affects extrapulmonary manifestations 
of SSc, including cutaneous sclerosis, and this may in turn affect 
PROs (36). Our findings indicate that improvements in cutaneous 
sclerosis, particularly among patients with dcSSc, are associated 
with improvements in PROs (eg, HAQ-DI, TDI, and SF-36 PCS).
With the present results, we found no significant correlation 
at baseline between the FVC%-predicted and dyspnea (BDI or 
HRQOL), with the exception of a weak correlation with the LCQ. 
On the other hand, at baseline, the DLCO%-predicted and the 
quantitative extent of ILD and fibrosis scores significantly cor-
related with the BDI and SGRQ. These findings suggest that 
when evaluating disease severity of SSc-ILD, these additional 
 assessment measures may provide a more comprehensive 
 understanding of a patient’s experience with the disease and 
could help inform treatment decisions.
We did find that an improvement in the FVC%-predicted and 
DLCO%-predicted was significantly associated with an improve-
ment in HRQOL (SF-36, HAQ-DI, and SGRQ) and dyspnea (TDI). 
These results illustrate that underlying changes in lung func-
tion and physiology may lead to meaningful changes in how a 
patient feels and functions. Consistent with this hypothesis, our 
prior analysis of SLS I and II demonstrated that clinically mean-
ingful improvements in the FVC%-predicted were associated with 
improvements in the PCS, TDI, and HAQ-DI scores (37).
We also examined the course of the TDI and SGRQ scores 
using a joint model approach to adjust for nonignorable missing 
data and baseline disease severity and demonstrated significant 
improvements in these measures over the 2-year trial. For the TDI, 
there was a steady increase (improvement) in TDI scores during 
the trial in both treatment groups. Similarly, there was a steady 
decrease (improvement) in SGRQ scores during the trial in both 
treatment groups. Both the TDI and SGRQ scores continued to 
improve in year 2, even in patients randomized to receive 1 year of 
CYC followed by 1 year of a placebo. Of note, 10 participants in 
the CYC arm began treatment with potentially disease-modifying 
immunosuppressant therapy during year 2 of the study (azathi-
oprine [n = 2], MMF [n = 7], and CYC [n = 1]) (38), raising the 
 possibility that the improvements that occurred during this time 
period could have been influenced by this additional therapy. In 
SLS I, we also appreciated significant improvements in the course 
of the TDI score beyond the 12-month treatment period (persisted 
until 18 months), suggesting that the effects of CYC persist even 
after the treatment is stopped for at least 6 months (39).
We observed a slight worsening of SGRQ scores at month 24 
compared with month 21 in both treatment groups. This was likely 
due to the fact that patients who withdrew from active  treatment 
Table 4. Correlations between the change in PROs and the change in objective measures of SSc-ILD disease severity in SLS II from baseline 
to 24 moa
  FVC% DLCO% QLF-ZM QLF-WL QILD-ZM QILD-WL mRSS, All mRSS, dcSSc mRSS, lcSSc
SF-36 PCS 0.30* 0.29* −0.14 −0.27* −0.18 −0.20 −0.30* −0.37* −0.008
SF-36 MCS 0.08 0.15 0.08 −0.02 0.06 0.08 0.05 0.03 −0.04
HAQ-DI −0.32* −0.34* 0.02 0.04 0.07 0.00 0.36* 0.41* 0.31*
TDI 0.42* 0.28* −0.14 −0.24* −0.26* −0.29* −0.35* −0.47* 0.05
LCQ 0.06 0.19 0.12 −0.04 −0.12 −0.15 −0.06 −0.09 0.04
SGRQ −0.29* −0.32* 0.03 0.14 0.21* 0.15 0.14 0.2 0.08
UCLA GIT 2.0 
(total score)
−0.13 −0.12 −0.02 0.03 0.04 0.02 0.14 0.12 0.21
UCLA GIT 2.0 
(reflux)
−0.05 −0.09 −0.06 0.07 0.10 0.17 0.11 0.07 0.24
Abbreviation: dcSSc, diffuse systemic sclerosis; DLCO%, diffusing capacity for carbon monoxide; FVC%, forced vital capacity; HAQ-DI, Health 
Assessment Questionnaire Disability Index; LCQ, Leicester Cough Questionnaire; lcSSc, limited systemic sclerosis; MCS, mental component 
summary; mRSS, modified Rodnan skin score; PCS, physical component summary; QILD, quantitative interstitial lung disease; QLF, quantitative 
lung fibrosis; SF-36, Short Form 36; SGRQ, St. George’s Respiratory Questionnaire; SLS, Scleroderma Lung Study; SSc-ILD, systemic sclerosis-
related interstitial lung disease; TDI, Transitional Dyspnea Index; UCLA GIT 2.0, University of California, Los Angeles Gastrointestinal Tract 2.0; WL, 
whole lung; ZM, zone of maximal involvement.
a Bold values denote at least medium correlation coefficients (r ≥ 0.3). 
*P < 0.05. 
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during the study were encouraged to return for the final 24-month 
study visit; therefore, this SGRQ assessment included participants 
who were not on active therapy.
The improvements appreciated in the joint model analy-
sis of the SGRQ and TDI scores mirrored the improvements we 
observed in the joint model of analysis of the FVC%-predicted in 
SLS II (9). The peak improvement in the FVC%-predicted in both 
treatment arms occurred at 21 months. In the present analysis, 
we also observed peak improvements in the SGRQ score at this 
time point (the TDI score was not obtained at 21 months). These 
findings further support the results of our correlation analyses, 
demonstrating that improvements in lung function are accom-
panied by parallel improvements in patients’ perception of their 
breathlessness.
Changes in quantitative radiographic scores for lung fibro-
sis and ILD correlated poorly with changes in all of the PROs, 
with the exception of dyspnea as assessed by the TDI. These 
findings suggest that the relationship between the radiographic 
progression of ILD and how a patient feels and functions is likely 
influenced by other factors. These factors could include a patient’s 
level of physical conditioning and the presence of comorbidities 
that limit mobility, such as arthritis. However, the participants in 
this trial did experience improvements in their overall health status 
(eg, SF-36 MCS, SF-36 PCS, and HAQ-DI). Taken together, these 
results may signify that treatment with CYC and MMF improves 
health outcomes in patients with SSc by also exerting beneficial 
effects on extrapulmonary features of SSc (eg, improvements in 
cutaneous sclerosis and arthritis).
The results of this study should be interpreted in the con-
text of specific limitations. A substantial number of patients with-
drew prematurely from active treatment during the study (CYC: 
44%; MMF: 30%). Although the joint model analysis adjusts for 
nonignorable missing data from dropouts (33), the high attrition 
rate in this trial could lead to biased estimates. We are reassured, 
however, that the improvements we observed in all of the PROs 
were robust and sustained over the course of the trial. Another 
limitation is that although most of the PROs were assessed every 
3 months, the TDI score was only assessed every 6 months. Addi-
tional data points for the TDI, especially earlier in the course of the 
trial, may have allowed us to further explore how breathlessness 
changes in response to treatment with CYC and MMF. Nonethe-
less, the joint model results clearly demonstrate an improvement 
in the course of the TDI score with these therapies. Finally, the 
MCID estimates applied in the article may be influenced by differ-
ent aspects of the disease and other medical conditions. The data 
should be interpreted with this caveat in mind.
Strengths of this work include the scientific rigor of SLS II, a 
study that used the expertise of experienced SSc investigators at 
each study site and went to great lengths to ensure quality data 
collection and management. Another strength of this study is the 
use of a diverse array of PROs. Because SSc is a systemic disease 
that affects multiple organ systems, it is important to understand 
how various PROs change in response to particular treatments. 
As new treatment options for SSc emerge, understanding how 
these various treatment options affect different aspects of a 
patient’s overall health may help guide treatment selection and 
continuation.
In summary, treatment with oral CYC and MMF led to clini-
cally meaningful improvements in overall health status, function, 
and breathlessness in patients with SSc-ILD, bearing in mind the 
limitations noted previously. Improvements in breathlessness par-
alleled improvements in lung function to a modest degree despite 
the finding that the baseline level of restrictive ventilatory impair-
ment did not correlate with how a patient felt. Above all, the find-
ings of this study demonstrate that a comprehensive evaluation 
combining pulmonary physiology, the radiographic extent of fibro-
sis, and PROs is essential to understanding the impact of treat-
ment on progression of ILD in SSc.
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